MIG Capital leads €13 million Series A financing of microbiome therapeutics biotech mbiomics
- mbiomics is leveraging its tailored high-precision bacterial profiling platform to accelerate the development of effective microbiome-based therapeutics
- Consortium led by MIG, with participation from High-Tech Gründerfonds, Bayern Kapital and private seed investors
- The funds raised will allow mbiomics to build its platform, embark on strategic partnerships and significantly expand its R&D teams and facilities
Munich, 23 March 2023
MIG Capital AG, one of Germany’s leading venture capital firms, announced today that it is investing in mbiomics GmbH, a pioneering microbiome biotech company developing the first generation of effective microbiome-based therapeutics, as part of a first closing of a €13 million Series A round. The financing was led by MIG, with participation from High-Tech Gründerfonds and Bayern Kapital alongside a pool of private seed investors. mbiomics will use the proceeds to embark on strategic partnerships, significantly expand its Munich laboratory facilities and R&D teams in Germany, and potentially increase US activities.
mbiomics uses its proprietary high-resolution profiling platform and computational techniques to generate precision data on microbiota modulation. The technology provides an improved understanding of the complex interactions between the gut microbiome and the host, allowing mbiomics to design more effective microbial consortia that can be delivered to patients as precision therapies. mbiomics’ core technology also improves patient selection and monitoring for clinical trials, and thus creates a competitive edge.
“We are thrilled to have the support of such a strong group of investors who share our vision of using the power of the gut microbiome to develop targeted therapies,” said Dr. Laura Figulla, co-founder and CEO of mbiomics. “This funding will enable us to build our platform, accelerate the identification of our first lead drug candidates, and speed up the research efforts towards clinical validation.”
With the announced closing, mbiomics is in a position to spearhead the emerging field of synthetic microbial consortia with the potential to revolutionize the treatment of a wide range of diseases, from cancer to inflammatory bowel diseases.
Dr. Matthias Kromayer, Managing Partner of MIG Capital, commented: “We are delighted to announce our investment in mbiomics and to back its journey to develop a truly innovative therapeutics platform. The company’s leading-edge approach of combining emerging technologies with the most advanced microbiome research has the potential to significantly improve patient outcomes. We look forward to supporting its ongoing research towards clinical development.”
About mbiomics
mbiomics GmbH, founded in 2020 and based in Munich, Germany, is a privately held biotech company, with a focus on developing the first generation of effective live bacterial therapeutics (LBT). The company is leveraging its tailored microbiome diagnostic platform to overcome current bottlenecks in LBT development – by generating precision profiling data, selecting better informed consortia, improving patient stratification and patient monitoring for clinical trials.
For more information, please visit the company’s website at www.mbiomics.com or contact info@mbiomics.com.
About MIG Capital
MIG Capital is one of the leading German VC investors. MIG invests in young deep tech and life sciences companies in German-speaking Europe and beyond. The company has so far invested over €680 million in about 50 companies. MIG’s portfolio companies develop innovations in areas such as biopharmaceuticals, energy and environmental technologies, advanced computing, digitization / IoT, medical technology and digital health. The MIG investment portfolio currently comprises 30 companies.
MIG’s investment team consists of a committed group of experts of engineers, biologists, scientists and investors who use analytical and creative processes to evaluate the risks and opportunities of business models and technologies. Their reputation, experience and network provide excellent access to companies, institutions and decision-makers in order to support the growth of their portfolio companies.
In recent years, MIG Capital realized more than ten successful sales, including more recently the portfolio companies Siltectra (to Infineon, 2018) and Hemovent (MicroPort, 2021), and led BRAIN (in 2017), NFON (in 2018), BioNTech (in 2019) and Immatics (in 2020) to listings on stock exchanges.
For further information, please visit: www.mig.ag, www.mig-fonds.de
Contact MIG
Laura Pivac-Bieser, MIG Capital AG
+49-89-94382680
Media Inquiries
MC Services
Raimund Gabriel, Dr. Johanna Kobler
+49-89-210228-0